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1. Introduction
Human parvovirus B19 (PVB19) is a nonenveloped 
member of the family Parvoviridae. It typically infects 
erythroid precursor cells and has a cytotoxic effect on 
them. Therefore, a pause of erythropoiesis occurs, which 
is the most obvious feature of parvovirus infections. In 
many patients this transient pause of erythropoiesis does 
not cause a problem; however, in those with problems such 
as hemolytic anemia, severe aplastic anemia crisis might 
be seen (1,2). 
The virus is generally spread by respiratory route, but 
blood transfusion is an alternative transmission route (3). 
PVB19 viremia occurs 1 week after the exposure and lasts 
at least 5 days. It reaches its highest level on the second day. 
Towards the end of the viremic period, immunoglobulin 
M (IgM) antibodies are detected. Generally, this detection 
is on days 10–14 of the infection. IgM positivity lasts until 
the 5th month. However, in some people, it may last longer. 
Immunoglobulin G (IgG) type antibodies become positive 
after 15 days and stay positive at higher titers for months. 
These antibodies can be analyzed using enzyme-linked 
immunosorbent assay (ELISA), radioimmunoassay, and 
chemiluminescence or immunofluorescence methods (4). 
Although epidemiological features of the infection do not 
change, IgG positivity is found in 2%–21% of children at 
ages range between 1 and 5, in 30%–40% of adolescents, in 
40%–60% of adults, and in more than 85% of the elderly 
population (5).
The main objective of professionals dealing with 
this issue is to ensure access to safe and effective blood 
components for patients who are in need of blood 
transfusion. Blood products obtained from plasma pools 
and PVB19 contamination are especially important for 
blood banking (5). Iatrogenic transmission is seen when 
a high level of viremia is present in the primary infection 
or if there is a virus load of more than 1012 geq/mL in early 
periods of acute infection in asymptomatic blood donors 
(6). However, in plasma products processed with solvent 
detergent technology, though HIV and hepatitis B and C 
are inactive, PVB19 is not affected because of its nonlipid 
enveloped structure. It is also resistant to heat and if the 
plasma is exposed to dry air at 80 °C for 72 h, there is no 
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inactivation (5). PVB19 DNAs are detected in 50%–80% 
of nonviral inactivated factor VIII concentrates and 
30%–50% of IX concentrates inactivated with the solvent/
detergent method (7). However, there are limited data 
on patients having symptomatic infections transmitted 
by virus-containing blood components. Most cases of 
seroconversion are shown in asymptomatic receivers (8).
Infection does not occur if the PVB19 viral load of 
plasma-derived products is less than 103–104 geq/mL. The 
explanation for this might be the inadequacy of the amount 
causing an infection or the existence of neutralizing 
antibodies in the pool from which the plasma-derived 
products were obtained. Receiver factors also have an 
important role in the infection. PVB19 antibodies hinder 
reinfection and most adults have seropositivity for PVB19 
(9,10). However, in the United States and Europe, there 
is permission for a maximum of 104 PVB19 viral load in 
plasma-derived blood products (11,12). 
The prevention of parvovirus B19 transmission is 
especially important for patient groups with immune 
deficiency or hemolytic anemia. In these groups, a viral 
load of more than 107 presents a high risk (4,9).
To prevent the use of PVB19-contaminated blood 
components is the only way to prevent the transmission of 
this infection via blood. 
2. Materials and methods
2.1. Study design
Nine hundred and eighty-eight blood samples were taken 
from individuals admitted to a university blood bank 
between 2012 and 2014. They were eligible for blood 
donation (based on blood donor database registers, blood 
donor questionnaires, and whole blood count results). 
Blood samples were centrifuged and separated serums 
were kept at –80 °C until study time. All procedures 
performed in studies involving human participants 
were in accordance with the ethical standards of the 
institutional and/or national research committee and with 
the 1964 Helsinki declaration and its later amendments 
or comparable ethical standards. The blood samples were 
taken from the blood donors in accordance with Gazi 
University Medical Faculty Ethics Committee Approval 
Document No. 184.  
2.2. Detection of parvovirus B19 IgM and IgG antibodies
For parvovirus B19 IgM and IgG detection, two different 
commercial ELISA kits were employed. The NovaLisa 
parvovirus B19 IgM and IgG ELISA kits (NovaTec 
Immundiagnostica GmbH, Germany) were used for 
PVB19 screening and PVB19 IgM-positive samples and 
90 randomized IgG-positive samples were confirmed 
via DRG parvovirus B19 IgM and IgG ELISA kit (DRG 
Instruments GmbH, Germany). The serum samples were 
diluted with sample dilution buffer at a ratio of 1:100 for 
DRG IgG and NovaLisa IgM and IgG tests. For DRG IgM 
assay, the serum samples were diluted at a ratio of 1:50, then 
diluted again with an IgG-RF-Sorbent solution within the 
kit at a ratio of 1:1. The assays were performed according 
to the manufacturer’s instructions. At the end of the study, 
optical densities (ODs) of the wells in the microplate were 
measured in 450/620 nm wavelength (Plate Reader, DAS, 
Italy) and the results were evaluated.
2.3. Evaluation of the results
According to validation measurements of the assay in the 
NovaLisa Parvovirus B19 IgM and IgG ELISA kits, the 
test is considered to be operated properly if the substrate 
blank well is less than 0.100, the negative control is less 
than 0.200, the cut-off value is between 0.150 and 1.300, 
and the positive control is higher than the cut-off value. 
The mean of the two cut-off values is taken. If OD values 
of the samples are 10% and higher than the cut-off value, 
the result is considered as positive, and if they are lower, 
the result is considered to be negative. The sensitivity and 
specificity of the kit were indicated as 95%.
According to the DRG parvovirus B19 IgM and IgG 
ELISA kits, the test is considered to be performed properly 
if the substrate blank well is less than 0.100, the negative 
control is less than 0.200, the cut-off value is between 0.350 
and 0.850, and the positive control is between 0.650 and 
3.000. The mean of the two cut-off values was taken. If OD 
values of the cut-off value were 20% and higher than the 
cut-off value, the result was positive. If they were 15% and 
lower, it was negative. The instruction manual of the kit 
declared sensitivity and specificity as 100%.
2.4. Statistical analysis 
SPSS 15 (SPSS Inc., Chicago IL, USA) was used for the 
evaluation of the data obtained from the study and to 
form tables. The data were presented in tables as numbers 
and percentages. The differences between parvovirus IgM 
and parvovirus IgG positivity regarding both sex and age 
groups were analyzed using the Pearson chi-square test. 
Finally, the significance level was P < 0.05 in all statistical 
analysis.
3. Results
The results obtained at the end of the study and their 
distribution concerning age and sex are presented in 
Tables 1 and 2.
There was a significant difference between both 
parvovirus IgM (χ2 = 8.038; P = 0.045) and IgG positivity 
rates (χ2 = 69.003; P < 0.001) in terms of age. Parvovirus 
IgM positivity was at its highest rate in the age group of 
41–50 years and lowest in the 18–30 age group. On the 
other hand, the parvovirus IgG positivity rate was highest 
at 31–40 years and lowest at ≥51 years. Although there 
was no significant difference between parvovirus IgM 
positivity in terms of sex (χ2 = 1.354; P = 0.245), parvovirus 
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IgG positivity rates were significantly different (χ2 = 4.192; 
P = 0.041). Finally, the parvovirus IgG positivity rate 
was significantly higher in women (65.40%) than men 
(57.20%). 
4. Discussion
Due to advances in transfusion medicine, blood-borne 
viral infection frequency has decreased recently. This 
was achieved using certain strategies such as blood 
donor selection, development of screening methods 
for the viral organism, and widespread use of viral 
inactivation methods concurrently. The use of nucleic acid 
amplification technologies has also shortened the window 
period and contributed to blood transfusion safety. PVB19 
may lead to serious clinical complications in pregnant 
women, children with hematological problems, and 
patients with immune deficiencies. If parvovirus is studied 
using different methods to analyze the blood of donors, 
one parvovirus case in 20,000 to 50,000 donations can be 
detected. In epidemic periods, this can be as high as one 
case in 260 blood donors (13).  
In Turkey, there are limited data on parvovirus 
epidemiology. Türk Dağı et al. investigated IgG frequency 
in a study carried out in Konya in 2010. Their study group 
included blood donors 18–60 years old and children 
admitted to the hospital for various reasons. In 631 blood 
donors from the adult group, PVB19 IgG positivity was 
36% (14). In 2012 Motor et al. analyzed parvovirus B19 
seroprevalence in adults with essential hypertension in 
Hatay. In the 45 individuals who formed the healthy 
control group of the study, IgM positivity was 15.6% 
and IgG positivity was 31% (15). Moreover, Erden et al. 
evaluated the relation between Hashimoto thyroiditis and 
PVB19 infection in 2013. In healthy participants making 
up the control group in this study, the IgM positivity was 
5.7% and the IgG positivity was 22.9% (16). Motor et al. 
analyzed the role of parvovirus in patients with ankylosing 
spondylitis in 2014. In the control group of this study, 
IgM positivity was 4.3% and IgG positivity was 30% (17). 
On the other hand, an IgM positivity of 3.9% and an IgG 
positivity of 58.9% were determined in our study. In all the 
studies mentioned above, the results showed significant 
variations. These variations may have occurred because all 
the data except one set came from control groups; there 
may also be seasonal and/or geographical differences, 
there are variations in the age distributions among the 
groups, and, finally, the study groups in other studies were 
not large enough.
The frequency of IgG antibodies against parvovirus 
B19 infection increases with age and has geographical 
differences. In Chile in 2007, for example, the frequency in 
blood donors (18–64 years old) was 54.8% (18), which is 
in accordance with our results. In Poland, the first peak for 
parvovirus infection was at a preschool age and by the age 
of 40 the rate was as high as 80% (19). Furthermore, 40% of 
women of child-bearing age were reported to be at risk of 
parvovirus B19 infection, especially during epidemic years. 
In Australia, seroprevalence for parvovirus B19 was 51% at 
ages of 10–19 and 78% at ages of >50 (20). In England and 
Wales, seropositivity was 50%–60% in young adults, but 
85% after the age of 70 (21). A study done in blood donors 
in 2004 in Italy revealed that the seropositivity rate was 
77% between the ages of 18 and 27, and the rate was 88.5% 
between the ages of 48 and 57 (22). However, the highest 
seropositivity rate was found between the ages of 31 and 40 
in our study. In contrast with the literature, it was observed 
that there is a significant decrease in the seropositivity rate 
especially after 50 years.
Seropositivity rates of parvovirus infection indicate 
geographical differences. In Far East Asian countries 
Table 2. Distribution of blood donors according to age groups 
and sex.
Blood donors age groups Male Female Total
18–30
31–40
41–50
51–65
268
222
104
189
68
58
50
29
336
280
154
218
Total 783 205 988
Table 1. Distribution of parvovirus IgM and IgG positivity according to age groups.
Age groups Blood donors number IgM positivity number IgM positivity percent IgG positivity number IgG positivity percent
18–30 336 8 2.38 202 60.3
31–40 280 14 5 200 71.7
41–50 154 11 7.14 100 64.7
51–65 218 6 2.75 80 36.6
Total 988 39 3.9 582 58.9
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seropositivity is lower than in the western world. For 
example, in Thailand, this rate was 10.94% in young adults 
in 2003 (23). In another Far East country, Malaysia, this 
rate for the same age group was 32% in 2002 (24). In a 
similar study carried out in 1998 in Spain, IgG antibodies 
were positive in 64.7% of blood donors, but IgM antibodies 
were not found in any participants (25). While the 
seropositivity rate of blood donors in Belgium was 74%, 
that of blood donors in Tunisia was 65% in 1997. This 
difference might originate from geographical differences 
between north and south (26). 
The methods that decrease parvovirus transmission 
in transfusion medicine are still under investigation. 
Among these methods being discussed are the nucleic acid 
amplification test (NAT), in which screening is done in a 
single case or in a small number of pools, and techniques 
that are applied in viral inactivation and detergent solvent 
methods such as multiple steps of superheating (3 days at 
80 °C), pasteurization, and nanofiltration (27). Screening 
of all blood donation with NAT-based algorithms is 
performed in Germany, Austria, Poland, and Japan 
(28,29). Not using plasma with higher than a certain 
amount of viral load (105 IU/mL) decreases the viral load 
in plasma pools and also diminishes the seroconversion 
or transmission rate of symptomatic diseases. However, 
this may destroy much of the plasma, so the maintenance 
of the system should be guaranteed (5). However, low 
transmission risk with transfusion brings the question of 
availability, especially in low endemic countries (30).
The largest study that shows the parvovirus B19 
seroprevalence in blood donors in Turkey was performed 
in this research and the ratios changing with age and sex 
were also presented.
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